Project Grant HT94252410930
Award Date
8/15/24
Completion Date
8/14/27
Dollars Obligated
$820K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,328,936 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a 3-year research project titled "Elucidating Tumor Intrinsic and Extrinsic Drivers of Mucosal Melanoma". The grant, awarded on Sep 30, 2023, will fund MGH's biomedical research efforts to study the genetic and epigenetic landscape of mucosal melanoma,...
The Department of the Army Medical Command, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $1,498,368 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a performance period from August 1, 2024 to July 31, 2027. The grant supports research to elucidate the molecular mechanisms of tumor-immune dynamics and evolution in response to radiation, in order to optimize treatment of high-...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $577,094 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at "Redirecting Viral Immunity to Eradicate Low Tumor Mutation Burden Lung Cancers." The award period runs from Aug 31, 2023 to Aug 29, 2025. As a leading academic medical center and research institution, MGH utilizes its...
This Project Grant award, valued at $1,618,114.00 and effective from April 1, 2025 to March 31, 2028, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports research conducted by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to define the role of anti-nephrin antibodies in the recurrence of focal segmental glomerulosclerosis post transplantation. This...
The Department of the Army Medical Command has awarded a $1,644,309 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The award, which runs from February 1, 2025, to January 31, 2028, will fund research aimed at "FUNCTIONAL MOLECULAR NETWORKS MODIFYING HIF2A ACTIVITY IN VHL TUMORS." As a renowned academic medical center and major recipient of federal...
The federal Project Grant award, totaling $1,270,020.00, was provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program. The award to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), supports the "Development of Personalized Cancer Vaccines Targeting Tumor Heterogeneity and Reprogramming the Cold Tumor Micro-environment in Kidney Cancer." This 4-year research project aims to...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $730,033 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to develop therapies targeting AMH signaling within the ovarian cancer tumor microenvironment. The award has a performance period from April 15, 2024 to April 14, 2027. As part of its extensive biomedical research portfolio,...
The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $1,865,846 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on July 1, 2024. The funding will support the project "TARGETING NEUROIMMUNE AND EPITHELIAL SIGNALING FOR ECZEMA TREATMENT" through June 30, 2028. MGH, a leading academic medical center and research institution, will conduct biomedical research,...
The U.S. Department of the Army Medical Command awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $443,170 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports the development of a transgene expression control switch for Friedreich ataxia gene therapies. This research aims to advance disease prevention, diagnosis, treatment, and management through basic, applied, and...
The federal Project Grant award with ID HT94252410711, titled "TARGETING HETEROGENEITY IN NF2-MUTANT TUMORS," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,568,220.00 grant, with a performance period from Sep 15, 2024 to Sep 14, 2027, was awarded to The General Hospital Corporation's Research Management Division, doing business as Massachusetts General Hospital (MGH). Through this funding, MGH will conduct...